Pharmaceuticals
IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH
SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 9, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today shared findings via a poster ...
2024-12-10 10:00
1312
2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC)
NANJING, China and GAITHERSBURG, Md., Dec. 9, 2024 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to discuss the clinical study of tinengotinib in combination with atezol...
2024-12-09 23:00
1680
Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial
* Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 * Appoints US-based Chief Commercial Officer, Andrew Udell * Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media. SYDNEY, Dec. 9, 2024 /PRNewswire/ -- A...
2024-12-09 21:00
1588
Dizal Presents Latest Data of DZD8586, a LYN/BTK Dual Inhibitor, in B-cell Non-Hodgkin Lymphoma at the 2024 ASH Annual Meeting
DZD8586 demonstrated encouraging anti-tumor activity with manageable safety and favorable pharmacokinetic (PK) characteristics in patients with B-NHL SHANGHAI, Dec. 9, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment o...
2024-12-09 18:00
1162
2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting
SHANGHAI, Dec. 8, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versus-Host Disease (cGvHD) who have either progressed or not responded to one or mo...
2024-12-09 10:40
1237
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
BEIJING, SHANGHAI and BOSTON, Dec. 8, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (Ame...
2024-12-09 08:42
1075
Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
OSAKA, Japan and MONTREAL , Dec. 5, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters:Osaka, Japan; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters:Montreal, Quebec, Canada; CEO:...
2024-12-06 07:56
1293
China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke
NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been approved for marketing by the National Medical Products Admini...
2024-12-04 18:10
1551
Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer
HONG KONG, Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study (AK104-IIT-018) of cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced or metastat...
2024-12-04 13:09
1429
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery
* VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery * Statistically and clinically meaningful reductions in inflammation and ...
2024-12-04 00:00
1686
Terumo Interventional Systems Announces Launch of Its R2P NaviCross Peripheral Support Catheter
– Provides interventionalists with optimal product choices for more complex radial-to-peripheral procedures– SOMERSET, N.J., Dec. 3, 2024 /PRNewswire/ -- Terumo Interventional Systems (TIS), a division of Terumo Corporation, is pleased to announce the launch and commercial availability of its R2...
2024-12-03 21:00
928
Samsung Biologics hosts ESG event with suppliers to strengthen decarbonization efforts
INCHEON, South Korea, Dec. 3, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today hosted its second Supplier ESG Day to share insights on sustainable management and encourage ESGactions among suppliers. Second of i...
2024-12-03 20:00
1287
Fangzhou Inc. Announces Inclusion of Its Shares in Hang Seng Hong Kong-Listed Biotech Index
HONG KONG, Dec. 3, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company's Ordinary Shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), will be included in the Hang Seng Hong Ko...
2024-12-03 18:47
1226
MGI Tech announces partnership with Universidad de San Martín de Porres to strengthen human genetics research
* The implementation of MGI Tech's next-generation genomic sequencing (NGS) technologies will strengthen scientific research in the country, enabling the identification of key genetic variations, contributing to disease prevention, and personalizing medical treatments. * A team of specialists...
2024-12-02 11:16
1135
BGM Group Ltd Pioneers Innovation in AI Technology, Fostering Holistic Integration of Healthcare and Insurtech
CHENGDU, China, Nov. 29, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), a leading global pharmaceutical enterprise, today announced its acquisition of the intelligent platform of AIX Inc. (NASDAQ: AIFU) ("AIX") valued at1 billion RMB (approximately $140 million). The ...
2024-11-29 23:58
4805
MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China
SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of its Phase III clinical trial of MRX-4 for injection transitioning to oral Contezolid tablets for the treatment of adult patients with complex sk...
2024-11-29 22:00
2558
Minghui Pharmaceutical Announces Positive Topline Results from Phase Ⅲ Trial of MH004 (Tofacitinib Etocomil) Ointment in Mild to Moderate Atopic Dermatitis
SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced positive topline results from its phase Ⅲ trial of MH004 (tofacitinib etocomil) ointment 1.0%, a twic...
2024-11-29 20:31
2714
Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference
HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce its participation in the upcoming 7th Annual Evercore HealthCONx Conference and Citi 2024 Global Healthcare Conference, both taking place inMiami. Akeso will participate in a firesid...
2024-11-29 10:23
1325
Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab
HONG KONG, Nov. 27, 2024 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce that two of its independently developed, globally pioneering bispecific antibody drugs—cadonilimab Injection (PD-1/CTLA-4 bispecific antibody) and ivonescimab Injection (PD-1/VEGF bi...
2024-11-28 11:58
1805
111, Inc. Announces Third Quarter 2024 Unaudited Financial Results
* Maintained Operational Profitability for the Third Consecutive Quarter * Operating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoY * Held Positive Operating Cash Flow for Three Consecutive Quarters SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company...
2024-11-27 14:00
1602
Week's Top Stories
Most Reposted
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
[Picked up by 335 media titles]
2025-01-18 03:30
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
[Picked up by 308 media titles]
2025-01-18 17:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 305 media titles]
2025-01-20 14:27
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 303 media titles]
2025-01-21 16:00
Infobip Research Unveils Opportunities for Brands to Engage Customers with Rich Communication Services (RCS) across APAC
[Picked up by 288 media titles]
2025-01-20 21:09
Most Read
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
2025-01-18 03:30
10361
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
2025-01-18 17:00
9391
Boosting Yeast Protein Production to Meet the Growing Global Demand for Alternative Proteins
2025-01-17 22:46
9156
Dongying's vibrant Spring Festival awaits visitors
2025-01-17 21:46
9026